After its first suspected Delta variant community case, New Zealand goes into short, sharp...
New Zealanders are back in their bubbles after Prime Minister Jacinda Ardern announced a three day alert level 4 lockdown for the entire country, and a seven day period for Auckland...
It will be a long, long wait for Covid herd immunity
Opinion: The ongoing crisis over the Covid-positive person who visited Wellington from Sydney raises questions about the Government’s zero Covid stance, writes Professor Ananish Chaudhuri.
Higher-educated and obese people eat less healthy during lockdown
Most Dutch people did not change their diets during the first Covid-19 lockdown, but more overweight and obese people said they ate less healthily...
Navigating the next phase of COVID-19: three critical issues for business leaders
Business leaders need to address questions on work processes, performance and virtual teams to improve productivity and engagement through the COVID-19 induced recession, says UNSW Business School.
Vaccination by inhalation
Delivering vaccines directly to the lungs can boost immune responses to respiratory infections or lung cancer, study finds.
UOW to conduct study on the pandemic experience of essential workers
Researchers from the University of Wollongong (UOW) Faculty of the Arts, Social Sciences and Humanities are seeking people who worked in supermarkets and quarantine hotels during the COVID-19 pandemic...
The flu, a cold, allergies or COVID-19? How to decipher symptoms
Let’s say you have a runny nose, headache and cough. Are they signs of COVID-19 or just a run-of-the-mill common cold?
The low-cost widely available drug that could fight COVID-19
A widely available and affordable drug, heparin, limits lung damage when inhaled by COVID-19 patients, according to world-first findings by researchers from The Australian National University (ANU).
Shaping Singapore’s future, together
“My hope is for Singapore to emerge as a fairer, greener, and more equal country, with a much stronger spirit of solidarity and shared purpose.”
Recruitment commences for Phase 1 clinical trial of two Melbourne-made COVID-19 vaccines
Melbourne researchers are calling on healthy people aged 18-70 living in Victoria to roll up their sleeves for a Phase 1 clinical trial of two Melbourne-made COVID-19 vaccines.
